Greenburgh-based pharmaceutical company Regeneron announced the results of four studies of its drug alirocumab, one of which showed the drug reduced levels of “bad cholesterol” by 61 percent.
The results of the studies, all of which met their primary efficacy endpoint, were presented over the weekend at a session of the ESC Congress 2014 in Barcelona.
“Across these four trials, alirocumab showed significant and sustained reductions in LDL-C over one year on top of standard-of-care statin therapy across different patient types,” said Dr. Jennifer Robinson, director of the University of Iowa’s Prevention Intervention Center and a professor of medicine at the university’s College of Public Health.
One of the trials was designed to evaluate the long-term safety and efficacy of 150 milligrams of alirocumab every two weeks against a placebo in patients with high cholesterol who were at high or very high cardiovascular risk. The study showed that after 24 weeks, there was a 61 percent reduction in LDL-C (“bad cholesterol”) levels in the alirocumab group, compared with a 1 percent increase in the placebo group, Regeneron reported.
Regeneron Pharmaceuticals Inc. developed alirocumab with Paris-based Sanofi.
Comments 1